In April 2020, Abiomed acquired medical device company Breethe, a startup that spun out of the University Of Maryland. The startup had developed a portable extracorporeal membrane oxygenation (ECMO) system that acts like an artificial lung, oxygenating and removing carbon dioxide from the blood of a patient in cardiogenic shock or respiratory failure. The technology, now known as the Abiomed Breethe OXY-1 System, received FDA 510(k) clearance later that year.
